Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report.

Abstract

Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223. Although the patient ultimately died from causes unrelated to the treatment before starting the third treatment course, we observed that radium-223 was more effective in areas closer to the bone cortex than in deeper tumor regions. Through histopathological analysis, we provide important mechanistic insights on the therapeutic effect of radium-223 in human prostate cancer bone metastases.

• Authors: Masato Dobashi, Dai Kouguchi, Yukiko Kanetsuna, Junichiro Ishii
• Journal: Urology case reports (Urol Case Rep) Vol. 32 Pg. 101230 (Sep 2020) ISSN: 2214-4420 [Print] United States
• PMID: 32420038 (Publication Type: Case Reports)
• Copyright: © 2020 The Authors.